Nicole Vitullo is 10% at Orexigen Therapeutics, Inc. (OREX). They have made 40 open-market trades across 16 companies since 2006, most recently 2023-06-15.
CIK 0001196863
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
22 open-market purchases totalling $93.8M since 2008, against 18 sales. Across 5 scored buys the stock is down 2.6% at ninety days, and 2.9 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 0% | 0% |
| Avg Move | -28.1% | -2.6% | -2.6% |
| Alpha | -22.3% | -2.9% | -2.9% |
| Scored | 5 | 5 | 5 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 63% | 13% | 38% |
| Avg Move | -5.3% | +5.1% | +4.4% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MRNS | SELL | 2021-03-15 | 2021-03-16 | $15.87 | $135K | -4.9% | -5.8% | +23.0% |
| ESPR | SELL | 2019-03-19 | 2019-03-21 | $44.66 | $609K | -2.2% | -6.0% | +14.1% |
| ESPR | SELL | 2019-03-19 | 2019-03-21 | $44.73 | $686K | -2.2% | -6.0% | +14.1% |
| ESPR | SELL | 2018-01-25 | 2018-01-26 | $71.79 | $1.7M | -10.0% | +8.2% | -7.8% |
| ESPR | SELL | 2017-12-06 | 2017-12-08 | $53.85 | $502K | +6.0% | +17.7% | +27.2% |
| ESPR | SELL | 2017-12-06 | 2017-12-08 | $53.85 | $502K | +6.0% | +17.7% | +27.2% |
| CLCD | SELL | 2016-04-28 | 2016-05-02 | $6.96 | $2.1M | -10.1% | +4.5% | +26.5% |
| EVOK | SELL | 2016-04-25 | 2016-04-27 | $5.07 | $415 | +2.5% | +13.8% | -67.4% |
| EVOK | SELL | 2016-04-19 | 2016-04-21 | $5.36 | $421K | -2.6% | +2.8% | -60.4% |
| EVOK | SELL | 2016-04-11 | 2016-04-13 | $5.22 | $392 | +6.3% | +3.4% | +110.3% |
| ACHN | SELL | 2015-11-09 | 2015-11-12 | $10.17 | $5.6M | -25.7% | -1.9% | -43.9% |
| ACHN | SELL | 2015-09-25 | 2015-09-29 | $8.22 | $77K | -25.7% | -1.9% | -1.9% |
| ACHN | SELL | 2015-08-14 | 2015-08-18 | $7.51 | $284K | -25.7% | -1.9% | -1.9% |
| NEOT | BUY | 2014-11-25 | 2014-12-10 | $14.00 | $980K | N/A | N/A | N/A |
| ALIM | SELL · 10b5-1 | 2014-01-15 | 2014-01-17 | $6.39 | $1.9M | -20.2% | +0.0% | +0.0% |
| RGDO | BUY | 2013-08-27 | 2013-08-28 | $4.00 | $3.0M | N/A | N/A | N/A |
| OCRX | BUY | 2013-07-15 | 2013-07-31 | $6.03 | $8.0M | N/A | N/A | N/A |
| ESPR | BUY | 2013-07-01 | 2013-07-02 | $14.00 | $4.0M | -35.3% | -0.8% | -0.8% |
| ALIM | SELL · 10b5-1 | 2013-06-20 | 2013-06-24 | $5.01 | $571 | -20.2% | +0.0% | +0.0% |
| ALIM | SELL | 2013-05-15 | 2013-05-17 | $4.60 | $204K | -20.2% | +0.0% | +0.0% |
| CADX | SELL · 10b5-1 | 2013-03-19 | 2013-03-21 | $5.20 | $216K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-19 | 2013-03-21 | $5.20 | $70K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-11 | 2013-03-13 | $5.36 | $2K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-07 | 2013-03-11 | $5.25 | $94K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-07 | 2013-03-11 | $5.25 | $2K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| VCYT | 22,730 | $981K |
| ACHN | 36,431 | $246K |
| AKAO | 1,987,049 | $219K |
| EVOK | 16,269 | $179K |
| ESPR | 36,918 | $118K |
| BNGO | 6,891 | $9K |
| CLVS | 51,013 | $4K |
| MRNS | 6,442 | $4K |
| OCRX | 7,333 | — |
| OREX | 50,643 | — |
| RGDO | 2,571,117 | — |
| SOMX | 15,456 | — |
| CADX | 2,429,454 | — |
| VOLC | 5,142 | — |
| DRTX | 16,529 | — |
| NEOT | 2,956,985 | — |
| PrivateUnlisted | 2,378,924 | — |
| Total | $251.4M |
Shares reported on the most recent Form 4, priced at the 2023-06-16 close. 9 holdings could not be priced and are excluded from the total.
| Scored | 8 | 8 | 8 |